Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? —a systematic review and meta-analysis

ConclusionClear clinically significant benefit was seen with the addition of NK1RAs in carboplatin-based chemotherapy. A global benefit of an NK1RA containing regimen for the whole MEC category cannot be attested yet and warrants more randomized trials exclusively testing pure MEC regimens without carboplatin.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research